CRUK Oxford Centre
  • Home
  • About
    • Vision & Strategy
    • Governance
    • Membership
    • The Oxford Team
  • Research & Researchers
    • Oxford’s Cancer Researchers
    • Research Showcase
      • Cancer Big Data
      • Early Detection
      • Engineering Better Outcomes
      • Digestive Tract Cancer
      • Immunity, Infection and Inflammation
      • Blood Cancers
    • Networks & Consortia
      • Oxford Lymphoid Disorders Study Group
      • Advanced Radiotherapy Technologies Network
      • Cellular-Molecular Pathology
      • PathLAKE
      • S:CORT
      • ACRCelerate
      • EHNBPCCG
      • EPIC
      • Southampton Immune Accelerator
      • Marseille-Oxford Collaboration
      • NCIMI
      • Sichuan University (West China Hospital)-Oxford University Gastrointestinal Cancer Centre
      • PancrImmune
    • Clinical Studies
      • NuTide 301
      • TARDOX
  • Centre Support
    • Funding Opportunities
      • Development Fund
        • Previous Awards
      • CRUK Funding Calls
      • Other Funding Calls
    • Clinical Positioning Services
    • Translational Histopathology Laboratory
      • Multi-plex Immunofluorescence (IF) Imaging
      • RNAscope®
      • TMA Construction
      • Slide Scanning, Automated Tissue Segmentation and Scoring
      • Single and Double Antibody Tissue Staining (Chromogenic IHC)
      • Antibody Optimisation
      • Hematoxylin & Eosin (H&E) Staining
      • Tissue Processing, Embedding and Sectioning
    • Oxford Molecular Diagnostics Centre
    • Patient & Public Involvement in Research
    • Public Engagement
    • Informatics Tools
    • Sample Collection
    • Clinical Trial Support
    • Branding Toolkit
  • Oxford Cancer Academy
    • DPhil in Cancer Science Programme
      • Non-clinician DPhil Studentships
      • Clinical DPhil Studentships & Fellowships
      • Alumni destinations
  • News
  • Events
    • Annual Symposium
  • Contact
    • Contact us
    • Locate the Centre
  • Search
slider-1-back

Pioneering Early-Phase Clinical Trials

Harnessing world leading science to cure cancer

Find out more about us
bokeh-slider-background

Collaborating Across our Research Network

We generate synergies with fellow leaders in Cancer Research

Find out more...

Collaboration between the Oxford Cancer Network and industry to improve patient care

  • Significant demand for more efficacious and better tolerated systematic therapies, including novel agents and combination therapies.
  • Oxford has world-leading early phase clinical trials infrastructure, partnering with industry to foster translational research collaborations
  • NuCana, our industry partner, works to transform nucleoside analogs- some of the most widely prescribed chemotherapy drugs such as 5FU- using ProTide technology

The Old Guard?

  • 5-FU is the backbone of therapy for a variety of different solid tumours and has been for the last fifty years
  • Produces the anti-cancer metabolite FUDR-MP
  • 5FU hampered by thee key resistance mechanisms: insufficient target (TS) inhibition, extensive drug degradation by dihydropyrimidine dehydrogenase (DPD), and poor drug activation
  • Toxic metabolites pose risk of hand-foot syndrome

Protide transformations

  • NUC3373 is designed to overcome resistance mechanisms associated with 5FU.
  • Non-clinical studies have shown 330x greater cytotoxicity in vitro than 5FU.
  • It shares the features common to all ProTides: the ability to enter cells without the need for membrane transporters; deliver the activated nucleotide analog; and avoid enzymatic degradation to potentially toxic compounds.
  • NUC-3373 can be infused over a much shorter time frame of 30 minutes – four hours compared to 46-hour continuous infusion required with 5-FU, due to it’s  considerably longer half-life.
NUC-3373 and 5FU mechanisms of action

Study

  • A two-part, phase 1 open label, dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC3373 in participants with advanced solid tumours.
  • Purpose: To establish the recommended phase 2 dose (RP2D) for NUC-3373 and test these further in expansion cohorts

Trial Information

Chief Investigator

Prof. Sarah Blagden

ClinicalTrials.gov Identifier

NCT02723240

Lay summary

Cancer Research UK

Publications and Presentations

Conference presentations

AACR 2016

ESMO 2017

ESMO 2018

  • Clinical Studies
    • NuTide 301
    • TARDOX
  • Networks & Consortia
    • ACRCelerate
    • Advanced Radiotherapy Technologies Network
    • Cellular-Molecular Pathology
    • EHNBPCCG
    • EPIC
    • Marseille-Oxford Collaboration
    • NCIMI
    • Oxford Lymphoid Disorders Study Group
    • PancrImmune
    • PathLAKE
    • S:CORT
    • Sichuan University (West China Hospital)-Oxford University Gastrointestinal Cancer Centre
      • Collaboration Projects
    • Southampton Immune Accelerator
  • Oxford’s Cancer Researchers
  • Research Showcase
    • Blood Cancers
    • Cancer Big Data
    • Digestive Tract Cancer
    • Early Detection
    • Engineering Better Outcomes
    • Immunity, Infection and Inflammation

Quick Links

  • Home
  • About
  • Research
  • Funding
  • Graduate studies
  • Events
  • Engagement
  • Sitemap
  • Privacy
  • Terms
  • Cookies
  • Branding Toolkit
  • LATEST NEWS

    • New sequencing methods for distinguishing DNA modificationsJanuary 27, 2021 - 12:01 am
    • New form of gift wrap drives male reproductive successJanuary 26, 2021 - 12:05 pm
    • Bowel cancer patients going undiagnosed due to COVID distruptionJanuary 15, 2021 - 10:47 am

    CONTACT

    You can keep in touch in a number of ways:

    • Visit the contact page
    • Tel: 01865 617043
    • cancercentre@oncology.ox.ac.uk
    • View the locate Centre page
    Followon TwitterSubscribeto RSS Feed

    OUR PARTNERS

    Cancer Research UK

    University Of Oxford

    Oxford University Hospitals NHS Trust

    © Copyright 2016 - CRUK Oxford Centre - Web design by Arnie
    Scroll to top